Estimated annual CO2e savings from emissions reduction initiatives by initiative type and GHG scope
Unit
i
The unit(s) of measurement applicable to the metric.
: Metric tonnes of CO2 equivalent (tCO2e)
Indicator
i
Indicators were developed by WBCSD. Learn more on the Methodology page.
: Business exposure to nature risks and opportunities
Metric type
i
The category of nature-related metrics. Learn more on the Methodology page.
: Other
Framework alignment notes
i
The details of a metric’s alignment to each framework, including where the same or similar metric can be found within the listed framework.
7.55.1
7.55.2
Refer to the PSCI's Decarbonization Playbook for the Pharmaceutical Industry for alignment to the metric
Refer to EFPIA's Clear Steps Toward a Greener Future - Pharmaceutical Sector’s Environmental Sustainability Statement (10.06.24) for alignment to metric
T8
Target example
[Company name] commits to achieve estimated annual CO₂e savings of [target amount] by [target year] from emissions reduction initiatives in [initiative type (e.g., energy efficiency, renewable energy, supply chain engagement)] across [GHG scope], compared to a [baseline year] baseline
Target Source: WBCSD target template
Sector
i
Each metric applies to one sector.
Pharmaceutical
Value chain stage
i
Each metric applies to one or more stages of the value chain aligned with the associated actions.
Raw MaterialsManufacturingEnd of Life
Metric assessment
i
The relevance and feasibility scores were determined by WBCSD member companies. Learn more on the Methodology page.
Relevance:Medium
Feasibility:Medium
Related actions
Set time-bound, science-based GHG reduction targets that are externally verified and aligned with climate goals
Reduce GHG emissions from operations and land use activities
Reduce GHG emissions in products
Develop and implement sourcing guidelines that prioritize sustainable commodities and suppliers committed to sustainable practices